Ixabepilone-associated peripheral neuropathy: Data from across the phase II and III clinical trials

Supportive Care in Cancer

Volumn 20, Issue 11, 2012, Pages 2661-2668

  Vahdat, Linda T ^a   Thomas, Eva S ^b   Roché, Henri H ^c   Hortobagyi, Gabriel N ^d   Sparano, Joseph A ^e   Yelle, Louise ^f   Fornier, Monica N ^g   Martín, Miguel ^h   Bunnell, Craig A ⁱ   Mukhopadhyay, Pralay ^j   Peck, Ronald A ^j   Perez, Edith A ^k  

^a Weill Cornell Breast Center   (United States)

^b KAISER PERMANENTE   (United States)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e ALBERT EINSTEIN CANCER CENTER   (United States)

^f NOTRE DAME HOSPITAL   (Canada)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k MAYO CLINIC   (United States)

more..

Author keywords

Breast cancer; Epothilone; Ixabepilone; Microtubules; Neuropathy

Indexed keywords

CAPECITABINE; IXABEPILONE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DYSESTHESIA; EARLY CANCER; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; SENSORY NEUROPATHY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATABASES, FACTUAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUBULIN MODULATORS; YOUNG ADULT;

EID: 84868507812     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1384-0     Document Type: Article

References (30)

1. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667
2. Rowinsky EK, Calvo E (2006) Novel agents that target tubulin and related elements. Semin Oncol 33:421-435
3. Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12:271-280
4. Pivot X, Dufresne A, Villanueva C (2007) Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer 7:543-549
5. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633-1642
6. Barohn RJ (1998) Approach to peripheral neuropathy and neuronopathy. Semin Neurol 18:7-18
7. Valero V, Holmes FA, Walters RS et al (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894
8. New PZ, Jackson CE, Rinaldi D et al (1996) Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 46:108-111
9. Rowinsky EK, Chaudhry V, Cornblath DR et al (1993) Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 15:107-115
10. Freilich RJ, Balmaceda C, Seidman AD et al (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology 47:115-118
11. National Cancer Institute: Common Toxicity Criteria, version 2.0
12. National Cancer Institute: Common Terminology Criteria for Adverse Events v 3.0
13. Postma TJ, Heimans JJ, Muller MJ et al (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739-744
14. Perez EA, Lerzo G, Pivot X et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414
15. Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217
16. Sparano JA, Vrdoljak E, Rixe O et al (2010) Randomized phase III trial of ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28:3256-3263
17. Baselga J, Zambetti M, Llombart-Cussac A et al (2009) Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 27:526-534
18. Bunnell C, Vahdat L, Schwartzberg L et al (2008) Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 8:234-241
19. Denduluri N, Low JA, Lee JJ et al (2007) Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25:3421-3427
20. Low JA, Wedam SB, Lee JJ et al (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734
21. Roche H, Yelle L, Cognetti F et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25:3415-3420
22. Thomas E, Tabernero J, Fornier M et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399-3406
23. Perez E, Pivot X, Vrdoljak E et al (2009) A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. Cancer Res 69, abstract 6140
24. Vansteenkiste JF, Lara PN Jr, Le Chevalier T et al (2007) Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25:3448-3455
25. Valero V, Bosserman LD, Yardley DA et al (2010) Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): a retrospective analysis of pooled data from two phase III clinical studies. J Clin Oncol 28 suppl, abstract 1051
26. Aghajanian C, Burris HA III, Jones S et al (2007) Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 25:1082-1088
27. Hussain M, Tangen CM, Lara PN Jr et al (2005) Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapynaive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 23:8724-8729
28. Postma TJ, Vermorken JB, Liefting AJ et al (1995) Paclitaxelinduced neuropathy. Ann Oncol 6:489-494
29. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803
30. Yardley DA (2009) Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist 14: 448-455